Case Study: A 55-year-old man diagnosed with anal cancer underwent GcMAF therapy as part of his treatment plan. Initially, he presented with symptoms of rectal bleeding, pain, and changes in bowel habits. 

 Imaging studies and biopsy confirmed the diagnosis of anal carcinoma. 

Treatment Plan: The patient received GcMAF injections daily using 1250ng, and microwave gcmaf cream applied intermittent throughout the day to the anus area, in addition to a much-reduced conventional treatment. 

Over the course of 4 months, his immune response was closely monitored, and adjustments to the GcMAF dosage were made based on his progress. 

Outcome :

 5-month check:  The patient experienced a significant reduction in tumor size, as evidenced by follow-up imaging studies. His overall health improved, with increased energy levels and reduced symptoms. 

 7-month check. Remission, combined therapy, the patient showed no signs of cancer recurrence and continued to receive maintenance doses of topical MicroproXtra GcMAF cream to support his immune system. He agreed to long-term changes in his diet and lifestyle, including adopting a healthier diet and increasing physical activity. He started playing golf and tennis, becoming more active than before his diagnosis. 

 This case illustrates the potential benefits of incorporating GcMAF into the treatment regimen for anal cancer, highlighting its role in enhancing the immune response and improving patient outcomes. 

Author of anal carcinoma and GcMAF, Maryjayne Aria  

#maryjaynearia #gcmaf #analcarcinoma #microproxtra